<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): October 29, 2008</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>Getting Ready Corporation<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>000-51314</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>30-0131755</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>100 North Fairway Drive,<BR>Suite 134<BR>Vernon Hills, Illinois<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>60061</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(847) 362-8200</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>N/A<BR></B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="justify" style="font-size: 10pt"><B>Item&nbsp;1.01 Entry Into a Material Definitive Agreement</B>


<P align="justify" style="font-size: 10pt; text-indent: 4%">On October&nbsp;29, 2008, Winston Laboratories, Inc. (&#147;Winston&#148;), a wholly-owned subsidiary of Getting Ready
Corporation (the &#147;Registrant&#148;) filed a new drug submission (NDS)&nbsp;in Canada, for CIVANEX<SUP style="font-size: 85%; vertical-align: text-top">&#174;</sup> Cream (civamide
0.075%) for the treatment of signs and symptoms of osteoarthritis, the first product Winston has developed under its
transient receptor potential vanilloid (TRPV)&nbsp;channel family technology.


<P align="justify" style="font-size: 10pt; text-indent: 4%">On October&nbsp;30, 2008, Winston entered into a License Agreement (the &#147;License Agreement&#148;) with sanofi-aventis Canada
Inc. (&#147;sanofi-aventis Canada&#148;) pursuant to which Winston granted sanofi-aventis an exclusive license to the Canadian
rights to Winston&#146;s proprietary transient receptor potential vanilloid (TRPV-1) modulator in formulations for topical
application.


<P align="justify" style="font-size: 10pt; text-indent: 5%">Under the terms of the License Agreement, sanofi-aventis Canada owns the rights to manufacture, develop and
commercialize civamide cream in Canada along with a second generation cream that is currently in development. In return
for granting sanofi-aventis Canada the Canadian rights to civamide cream, Winston will receive an upfront payment of
$1.9&nbsp;million (US), an additional $2&nbsp;million (CAD)&nbsp;upon regulatory approval of civamide cream in Canada, certain
milestone payments, and future royalties on net sales of civamide or the related second generation cream in Canada.


<P align="justify" style="font-size: 10pt; text-indent: 4%">A copy of Winston&#146;s press release announcing the filing of the NDS and its entry into the License Agreement is
filed herewith as Exhibit&nbsp;99.1.


<P align="justify" style="font-size: 10pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits</B>


<P align="justify" style="font-size: 10pt">(d)&nbsp;Exhibits


<P align="justify" style="font-size: 10pt">99.1 Press Release of Winston Laboratories, Inc., a wholly-owned subsidiary of Getting Ready Corporation, dated
<FONT style="white-space: nowrap">November&nbsp;5, 2008.</FONT>


<P align="center" style="font-size: 10pt">2





<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="justify" style="font-size: 10pt"><B>SIGNATURES</B>


<P align="justify" style="font-size: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">Date: November&nbsp;5, 2008</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>Getting Ready Corporation</B><br><br></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Joel E. Bernstein</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Joel E. Bernstein, M.D.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">3





<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="center" style="font-size: 10pt"><B>EXHIBIT INDEX</B>



<P align="justify" style="font-size: 10pt">99.1 Press Release of Winston Laboratories, Inc., a wholly-owned subsidiary of Getting Ready Corporation, dated
<FONT style="white-space: nowrap">November&nbsp;5, 2008.</font>


<P align="center" style="font-size: 10pt">4





<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">4




</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c76792e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 9844}]
{"company-data": {"conformed-name": "GETTING READY CORP", "cik": "0001302554", "assigned-sic": "2834", "irs-number": "300132755", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51314", "film-number": "081164571"}, "business-address": {"street1": "8990 WEMBLEY COURT", "city": "SARASOTA", "state": "FL", "zip": "34238", "phone": "941-966-6955"}, "mail-address": {"street1": "8990 WEMBLEY COURT", "city": "SARASOTA", "state": "FL", "zip": "34238"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 29, 2008
Getting Ready Corporation
(Exact name of registrant as specified in its charter)
Delaware
000-51314
30-0131755
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 North Fairway Drive,
Suite 134
Vernon Hills, Illinois
60061
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
(847) 362-8200
N/A
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry Into a Material Definitive Agreement
On October 29, 2008, Winston Laboratories, Inc. ("Winston"), a wholly-owned subsidiary of Getting Ready
Corporation (the "Registrant") filed a new drug submission (NDS) in Canada, for CIVANEX
®
Cream (civamide
0.075%) for the treatment of signs and symptoms of osteoarthritis, the first product Winston has developed under its
transient receptor potential vanilloid (TRPV) channel family technology.
On October 30, 2008, Winston entered into a License Agreement (the "License Agreement") with sanofi-aventis Canada
Inc. ("sanofi-aventis Canada") pursuant to which Winston granted sanofi-aventis an exclusive license to the Canadian
rights to Winston's proprietary transient receptor potential vanilloid (TRPV-1) modulator in formulations for topical
application.
Under the terms of the License Agreement, sanofi-aventis Canada owns the rights to manufacture, develop and
commercialize civamide cream in Canada along with a second generation cream that is currently in development. In return
for granting sanofi-aventis Canada the Canadian rights to civamide cream, Winston will receive an upfront payment of
$1.9 million (US), an additional $2 million (CAD) upon regulatory approval of civamide cream in Canada, certain
milestone payments, and future royalties on net sales of civamide or the related second generation cream in Canada.
A copy of Winston's press release announcing the filing of the NDS and its entry into the License Agreement is
filed herewith as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Press Release of Winston Laboratories, Inc., a wholly-owned subsidiary of Getting Ready Corporation, dated
November 5, 2008.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.
Date: November 5, 2008
Getting Ready Corporation
By:
/s/ Joel E. Bernstein
Joel E. Bernstein, M.D.
Chief Executive Officer
3
EXHIBIT INDEX
99.1 Press Release of Winston Laboratories, Inc., a wholly-owned subsidiary of Getting Ready Corporation, dated
November 5, 2008.
4